Data mining reveals a network of early-response genes as a consensus signature of drug-induced in vitro and in vivo toxicity

Pharmacogenomics Journal

Volumn 14, Issue 3, 2014, Pages 208-216

  Zhang, J D ^a   Berntenis, N ^a   Roth, A ^a   Ebeling, M ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

compound induced toxicity; early response genes; gene signature; TG GATEs; toxicogenomics

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; EARLY GROWTH RESPONSE FACTOR 1; GROWTH DIFFERENTIATION FACTOR 15;

ANIMAL CELL; ARTICLE; ATF3 GENE; CELL ASSAY; CELL DEATH; COMPUTER MODEL; CONSENSUS; CONTROLLED STUDY; DATA BASE; DATA MINING; DRUG CYTOTOXICITY; DRUG INDUCED TOXICITY; DRUG TOXICITY; EARLY RESPONSE GENE; EGR1 GENE; FGF21 GENE; GDF15 GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; GENE EXPRESSION PROFILING; IMMEDIATE EARLY GENE; TOXICITY TESTING;

ANIMALIA; RATTUS;

DATA MINING; GENE EXPRESSION PROFILING; GENES, IMMEDIATE-EARLY; HUMANS; IN VITRO TECHNIQUES; TOXICITY TESTS;

EID: 84901247883     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.39     Document Type: Article

References (68)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-716.
2. Arrowsmith J. Trial watch: phase II failures: 2008 - 2010. Nat Rev Drug Discov 2011a; 10: 328-329.
3. Arrowsmith J. Trial watch: phase III and submission failures: 2007 - 2010. Nat Rev Drug Discov 2011b; 10: 87.
4. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 2001; 120: 359-368.
5. Waters M, Stasiewicz S, Alex Merrick B, Tomer K, Bushel P, Paules R et al. CEBS - Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res 2008; 36(Suppl 1): D892-D900.
6. Kiyosawa N, Ando Y, Watanabe K, Niino N, Manabe S, Yamoto T. Scoring multiple toxicological endpoints using a toxicogenomic database. Toxicol Lett 2009; 188: 91-97.
7. Yuan B, Wang J, Cao H, Sun R, Wang Y. High-throughput analysis of the mutagenic and cytotoxic properties of DNA lesions by next-generation sequencing. Nucleic Acids Res 2011; 39: 5945-5954.
8. Steiner G, Suter L, Boess F, Gasser R, Cristina de Vera M, Albertini S et al. Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect 2004; 112: 1236-1248.
9. Heijne WH, Kienhuis AS, van Ommen B, Stierum RH, Groten JP. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics 2005; 2: 767-780.
10. Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 2005; 4: 461-467.
11. Chiang A, Butte A. Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther 2009; 85: 259-268.
12. Cami A, Arnold A, Manzi S, Reis B. Predicting adverse drug events using pharmacological network models. Sci Transl Med 2011; 3: 114ra27.
13. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012; 486: 361-367.
14. Fielden MR, Eynon BP, Natsoulis G, Jarnagin K, Banas D, Kolaja KL. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol Pathol 2005; 33: 675-683.
15. Powell CL, Kosyk O, Ross PK, Schoonhoven R, Boysen G, Swenberg JA et al. Phenotypic anchoring of acetaminophen-induced oxidative stress with gene expression profiles in rat liver. Toxicol Sci 2006; 93: 213-222.
16. Martin MT, Brennan RJ, Hu W, Ayanoglu E, Lau C, Ren H et al. Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. Toxicol Sci 2007; 97: 595-613.
17. Nioi P, Pardo IDR, Sherratt PJ, Snyder RD. Prediction of non-genotoxic carcinogenesis in rats using changes in gene expression following acute dosing. Chem Biol Interact 2008; 172: 206-215.
18. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007; 6: 636-649.
19. Consortium TEP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
20. Activation of Immediate Early Genes By Drugs of Abuse. In: Grzanna R, Brown R eds. NIDA Research Monograph Series. US National Institute on Drug Abuse, 1993.
21. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516.
22. Van Hummelen P, Sasaki J. State-of-the-art genomics approaches in toxicology. Mutat Res-Rev Mutat 2010; 705: 165-171.
23. Kiosawa N, Shiwaku K, Hirode M, Omura K, Uehara T, Shimizu T et al. Utilization of a one-dimensional score for surveying chemical-induced changes in expression levels of multiple biomarker gene sets using a large-scale toxicogenomics database. J Toxicol Sci 2006; 31: 433-448.
24. Hirode M, Omura K, Kiyosawa N, Uehara T, Shimuzu T, Ono A et al. Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy. J Toxicol Sci 2009; 34: 281-293.
25. Uehara T, Minowa Y, Morikawa Y, Kondo C, Maruyama T, Kato I et al. Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a largescale toxicogenomics database. Toxicol Appl Pharmacol 2011; 255: 297-306.
26. Gautier L, Cope L, Bolstad B, Irizarry RA. affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315.
27. Smyth G. Limma: Linear Models for Microarray Data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (eds). Bioinformatics and computational biology solutions using R and Bioconductor. Springer: New York, 2005.
28. Gelman A, Hill JH. Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge University Press: New York, 2007.
29. Jack J, Wambaugh JF, Shah I. Simulating quantitative cellular responses using asynchronous threshold Boolean network ensembles. BMC Syst Biol 2011; 5: 109.
30. Chang C-C, Lin C-J. LIBSVM: a library for support vector machines. ACM TIST 2011; 2: 1.
31. Holsapple MP, Pitot HC, Cohen SH, Boobis AR, Klaunig JE, Pastoor T et al. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 2006; 89: 51-56.
32. Hasegawa R, Furukawa F, Toyoda K, Jang JJ, Yamashita K, Sato S et al. Study for tumor-initiating effect of acetaminophen in two-stage liver carcinogenesis of male F344 rats. Carcinogenesis 1988; 9: 755-759.
33. Deutsch WA, Kukreja A, Shane B, Hegde V. Phenobarbital, oxazepam and Wyeth 14,643 cause DNA damage as measured by the Comet assay. Mutagenesis 2001; 16: 439-442.
34. Baek SJ, Kim J-S, Nixon JB, DiAugustine RP, Eling TE. Expression of NAG-1, a transforming growth factor-beta superfamily member, by Troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004; 279: 6883-6892.
35. Bottone FG, Moon Y, Alston-Mills B, Eling TE. Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene. J Pharmacol Exp Ther 2005; 315: 668-677.
36. Kumbrink J, Gerlinger M, Johnson JP. Egr-1 induces the expression of its corepressor Nab2 by activation of the Nab2 promoter thereby establishing a negative feedback loop. J Biol Chem 2005; 280: 42785-42793.
37. Fisher J, Henzinger TA. Executable cell biology. Nat Biotech 2007; 25: 1239-1249.
38. Johnson CL, Weston JY, Chadi SA, Fazio EN, Huff MW, Kharitonenkov A et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009; 137: 1795-1804.
39. Lee S-H, Krisanapun C, Baek SJ. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 2010; 31: 719-728.
40. Yin X, Wolford CC, Chang Y-S, McConoughey SJ, Ramsey SA, Aderem A et al. ATF3, an adaptive-response gene, enhances TGF-beta signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci 2010; 123: 3558-3565.
41. Loeffler I, Hopfer U, Koczan D, Wolf G. Type VIII collagen modulates TGF-betainduced proliferation of mesangial cells. J Am Soc Nephrol 2011; 22: 649-663.
42. Giraldo A, Barrett OPT, Tindall MJ, Fuller SJ, Amirak E, Bhattacharya BS et al. Feedback regulation by Atf3 in the endothelin-1-responsive transcriptome of cardiomyocytes: Egr1 is a principal Atf3 target. Biochem J 2012; 444(Pt 2): 343.
43. Alon U. An Introduction to Systems Biology: Design Principles of Biological Circuits. Chapman and Hall/CRC: Boca Raton, FL, USA, 2006.
44. Thomas R, Thieffry D, Kaufman M. Dynamical behaviour of biological regulatory networks - I. Biological role of feedback loops and practical use of the concept of the loop-characteristic state. Bull Math Biol 1995; 57: 247-276.
45. Kauffman S. Gene regulation networks: a theory for their global structure and behaviors. Curr Top Dev Biol 1971; 6: 145-182.
46. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. ATF3 and stress responses. Gene Expr 1999; 7: 321-336.
47. Cortes C, Vapnik V. Support-vector networks. Machine Learning 1995; 20: 273-297.
48. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-244.
49. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Sci Signalling 2006; 313: 1929.
50. Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 2007; 95: 5-12.
51. Gerets HHJ, Hanon E, Cornet M, Dhalluin S, Depelchin O, Canning M et al. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol In Vitro 2009; 23: 319-332.
52. Bailey WJ, Holder D, Patel H, Devlin P, Gonzalez RJ, Hamilton V et al. A performance evaluation of three drug-induced liver injury biomarkers in the rat: alphaglutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase. Toxicol Sci 2012; 130: 229-244.
53. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193: 287-292.
54. Sakamoto KM, Bardeleben C, Yates KE, Raines MA, Golde DW, Gasson JC. 50 Upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene 1991; 6: 867-871.
55. Gineitis D, Treisman R. Differential usage of signal transduction pathways defines two types of serum response factor target gene. J Biol Chem 2001; 276: 24531-24539.
56. Chen S-J, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y et al. The earlyimmediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006; 281: 21183-21197.
57. Moon Y, Yang H, Kim YB. Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells. Toxicol Appl Pharmacol 2007; 223: 155-163.
58. McMullen MR, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in Mice. Gastroenterology 2005; 128: 2066-2076.
59. Kim ND, Moon J-O, Slitt AL, Copple BL. Early growth response factor-1 is critical for cholestatic liver injury. Toxicol Sci 2006; 90: 586-595.
60. Tanaka Y, Nakamura A, Morioka MS, Inoue S, Tamamori-Adachi M, Yamada K et al. Systems analysis of ATF3 in stress response and cancer reveals opposing effects on pro-apoptotic genes in p53 pathway. PLoS One 2011; 6: e26848.
61. Kang Y, Chen C-R, Massagué J. A self-enabling TGF-beta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003; 11: 915-926.
62. Chen B, Wolfgang CD, Hai T. Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by Gadd153/Chop10. Mol Cell Biol 1996; 16: 1157-1168.
63. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K et al. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 2000; 15: 170-182.
64. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers Jr et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351-360.
65. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 2000; 20: 3742-3751.
66. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005; 23: 543-548.
67. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
68. Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011; 6: e18398.